Melanotan 1 vs Melanotan 2: Key Differences Explained
Melanotan 1 vs Melanotan 2 comes down to selectivity. MT1 (afamelanotide) acts mainly on the pigment receptor and became an approved drug. MT2 hits several melanocortin receptors at once, which is why it also affects libido and appetite, and why it never got approved.
Melanotan 1 (MT1, afamelanotide) is a linear 13-amino-acid analogue of α-MSH that acts mainly on the MC1 receptor, which controls skin pigment. It is FDA-approved as Scenesse for a rare light-sensitivity disorder. Melanotan 2 (MT2) is a shorter cyclic peptide that activates MC1, MC3, MC4 and MC5 receptors, so it also causes nausea, flushing, spontaneous erections and appetite loss. MT2 is not approved anywhere.
Melanotan 1 vs Melanotan 2 at a Glance
| Melanotan 1 (MT1) | Melanotan 2 (MT2) | |
|---|---|---|
| Other names | Afamelanotide, [Nle4, D-Phe7]-α-MSH, NDP-MSH | Melanotan II, MT-II |
| Structure | Linear, 13 amino acids | Cyclic, 7 amino acids |
| Main receptors | MC1R, the pigment receptor in skin | MC1R, MC3R, MC4R, MC5R (non-selective) |
| Effects seen in studies | Skin darkening, protection from light-induced reactions | Skin darkening, plus erections, sexual arousal, appetite loss |
| Common side effects | Nausea, headache, implant-site reactions, darker moles | Nausea, facial flushing, yawning, spontaneous erections, darker moles |
| Evidence | Phase 3 trials and post-approval safety data | Small early studies and case reports, no Phase 3 |
| Approved product | Scenesse implant (US, EU, Australia, others) | None. Its derivative bremelanotide is approved as Vyleesi |
What Is Melanotan 1?
Melanotan 1 came out of a University of Arizona research program in the 1980s that set out to make a stable version of α-melanocyte-stimulating hormone (α-MSH), the body's own signal for producing melanin. Natural α-MSH breaks down within minutes. Swapping two amino acids (norleucine at position 4 and D-phenylalanine at position 7) produced a far more stable analogue that keeps all 13 amino acids of the original hormone [1].
That analogue is now called afamelanotide. It binds mainly to MC1R, the receptor on melanocytes that switches pigment production from light pheomelanin to darker, more protective eumelanin [2].
Afamelanotide is the only melanotan that completed a full regulated development program. Its Phase 3 trials led to approval as Scenesse, a slow-release implant for adults with erythropoietic protoporphyria (EPP), a rare condition in which sunlight causes severe painful skin reactions. Scenesse is approved in the US, Europe, Israel and Australia [3]. Its developer, Clinuvel, is also running Phase 3 trials in vitiligo, with first results from the CUV105 study expected in December 2026 [4].
Research material: Melanotan 1 (MT1) research peptide.
What Is Melanotan 2?
Melanotan 2 was made by the same Arizona group as a shorter, cyclic version of the peptide. Closing the molecule into a ring made it more resistant to enzymes and more potent, but it also made it less selective. MT2 activates four of the five melanocortin receptors: MC1R in skin, MC3R and MC4R in the brain, and MC5R in glands [5].
That receptor spread explains its unusual profile. In early human studies MT2 darkened skin, but it also triggered erections in men with erectile dysfunction. In a small placebo-controlled study, erections occurred after 12 of 19 MT2 injections versus 1 of 21 placebo injections [6]. Those effects come from MC4R in the hypothalamus, the same pathway that also controls appetite.
MT2 never went through Phase 3 trials and has no approved indication anywhere. Most of what is known about its safety comes from case reports in people who bought it online for tanning [7].
Research material: Melanotan 2 (MT2) research peptide.
The Key Differences Between Melanotan 1 and 2
1. Structure and stability
MT1 is a linear 13-amino-acid chain, close to the natural hormone. MT2 is a 7-amino-acid ring. The ring protects MT2 from breakdown and lets it reach the brain more easily, which is one reason its effects extend beyond the skin [5].
2. Receptor selectivity
This is the core difference. MT1 is relatively selective for MC1R, so its effects stay mostly in the skin. MT2 is non-selective. In research terms, that makes MT1 a tool for studying pigmentation and photoprotection, and MT2 a tool for studying the wider melanocortin system, including sexual function and energy balance.
3. Pigmentation
Both peptides increase eumelanin in skin. The approved use of MT1 is not cosmetic tanning but reducing phototoxic reactions in EPP. MT2 is the one marketed online as a "tanning peptide", but no controlled trial has tested it for that purpose.
4. Sexual function and appetite
Only MT2 has clear effects here, through MC4R. Spontaneous erections, increased arousal and reduced appetite are reported in studies and case reports. MT1 does not show these effects to a meaningful degree.
5. Strength of evidence
MT1 has randomized Phase 3 data and years of post-approval monitoring. MT2 has a handful of small studies from the 1990s and 2000s plus case reports. The gap is large, and it matters when comparing claims about either peptide.
Where PT-141 (Bremelanotide) Fits In
Bremelanotide, also known as PT-141, is a metabolite of MT2 that was developed separately for its effect on sexual desire. It lacks MT2's C-terminal amide and has less effect on pigment. In 2019 the FDA approved it as Vyleesi for hypoactive sexual desire disorder in premenopausal women [8].
So the melanotan family has two approved descendants: afamelanotide from MT1 for light sensitivity, and bremelanotide from MT2 for sexual desire. MT2 itself is not approved, and the two should not be confused.
Side Effects and Safety: MT1 vs MT2
| Issue | Melanotan 1 | Melanotan 2 |
|---|---|---|
| Nausea, flushing | Reported, usually mild | Common, often dose-limiting in studies |
| Spontaneous erections, priapism | Not typical | Common erections; priapism needing urgent treatment in case reports [7] |
| Moles and melanoma | New or darker moles; skin checks required with Scenesse | Darker or new moles; case reports of melanoma and eruptive atypical moles [7] |
| Kidney and muscle | Not a recognized signal | Case reports of rhabdomyolysis and renal infarction [9] |
| Neurological | Headache | Case report of posterior reversible encephalopathy syndrome (PRES) [7] |
Case reports cannot prove that MT2 caused these events. Many involve unknown products of uncertain purity, and the true number of users is unknown. But the pattern of MT2 reports is broader and more serious than anything seen with regulated afamelanotide, and it matches its wider receptor activity.
Darkening of moles is a concern with both peptides, because it can make changes harder to spot. Approved Scenesse comes with a requirement for regular skin examinations for that reason [3].
Quality of Melanotan Products Sold Online
Most MT2 used outside research comes from unregulated online sellers, and testing has repeatedly found problems. In one analysis of grey-market vials labelled 10 mg, actual peptide content ranged from about 4.3 to 8.8 mg [10]. Seized samples tested by UK and Australian regulators have contained the wrong amount, impurities or no Melanotan at all [11].
For laboratory work this is the main practical point: the result of an experiment is only as good as the material. Each batch should come with a certificate of analysis showing identity by mass spectrometry and purity by HPLC. Our MT1 and MT2 pages show the batch COA in the Test Report tab.
Legal and Regulatory Status in 2026
- United States. Afamelanotide is approved only as Scenesse for EPP. MT2 is an unapproved drug, and the FDA has sent warning letters to companies selling it for tanning. MT2 was removed from the FDA's Category 2 compounding list in April 2026 after its nomination was withdrawn, but that did not make it eligible for compounding. It is not one of the six peptides covered by the October 2026 HHS policy [12].
- Australia. MT2 is a prescription-only medicine that is not approved for tanning. In 2026 the TGA fined an individual $101,412 through 27 infringement notices for supplying MT2 tanning products [13].
- United Kingdom. The MHRA has warned against MT2 since 2009, and products sold for tanning are unlicensed [11].
- Medical groups. In July 2026 the Skin Cancer Foundation issued a public warning against MT2 and other unapproved tanning products [14].
For background on the wider 2026 changes, see Are peptides legal? The HHS peptide policy explained.
Frequently Asked Questions
What is the main difference between Melanotan 1 and 2?
Selectivity. Melanotan 1 acts mainly on MC1R, the pigment receptor, so its effects stay in the skin. Melanotan 2 activates four melanocortin receptors, so it also affects sexual function, appetite and nausea.
Is Melanotan 1 the same as afamelanotide?
Yes. Afamelanotide is the official name of Melanotan 1. As a regulated drug it is sold as Scenesse, a slow-release implant approved for erythropoietic protoporphyria.
Is Melanotan 2 FDA-approved?
No. Melanotan 2 has no approved use anywhere in the world. Its derivative bremelanotide (PT-141) is approved as Vyleesi, but that is a different molecule.
Which is safer, Melanotan 1 or 2?
Melanotan 1 has a much larger and better-controlled safety record, from Phase 3 trials and post-approval monitoring. Melanotan 2 has no controlled safety data, and case reports describe serious events such as priapism, rhabdomyolysis, kidney infarction and melanoma.
Is Melanotan 2 related to PT-141?
Yes. PT-141 (bremelanotide) is a metabolite of Melanotan 2 that was developed for sexual desire disorders. It has less effect on skin pigment than MT2.
Do both Melanotan 1 and 2 cause tanning?
Both increase melanin in skin by activating MC1R. Neither is approved for cosmetic tanning, and both can darken existing moles, which is why skin monitoring is required in the approved use of afamelanotide.
Related Research
- Melanotan 2 (MT2): a scientific review
- Melanotan 1 (MT1, afamelanotide)
- PT-141 (bremelanotide)
- Are peptides legal? HHS peptide policy explained
All products are sold strictly for laboratory research. Not for human or veterinary use. This article summarizes published scientific literature and regulatory documents and is not medical advice.
Sources
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006.
- Wolf Horrell EM, Boulanger MC, D'Orazio JA. Melanocortin 1 receptor: structure, function, and regulation. Front Genet. 2016;7:95.
- Clinuvel Pharmaceuticals. SCENESSE® (afamelanotide 16 mg) approvals and prescribing information. clinuvel.com
- Clinuvel Pharmaceuticals. Update: SCENESSE® in vitiligo. July 28, 2026. clinuvel.com
- Cai M, Hruby VJ. The melanocortin receptor system: a target for multiple degenerative diseases. Curr Protein Pept Sci. 2016.
- Wessells H, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000.
- Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017.
- U.S. Food and Drug Administration. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women (Vyleesi). June 21, 2019.
- Nelson ME, et al. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol. 2012; Peters B, et al. Melanotan II: a possible cause of renal infarction. 2020.
- Breindahl T, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015.
- UK Medicines and Healthcare products Regulatory Agency (MHRA) public warnings on melanotan; summary in Refinery29, 2026. refinery29.com
- Superpower. Melanotan II: regulatory status (FDA Category 2 removal, April 2026). superpower.com
- Therapeutic Goods Administration. Individual issued 27 infringement notices for allegedly supplying Melanotan II. 2026. tga.gov.au
- The Skin Cancer Foundation. The Skin Cancer Foundation issues warning regarding Melanotan II. July 7, 2026. skincancer.org